NCT05078255已完成不适用
The Separate and Combined Effects of Long-term GIP and GLP-1 Receptor Activation in Patients with Type 2 Diabetes
Asger Lund, MD1 个研究点 分布在 1 个国家目标入组 61 人开始时间: 2022年1月27日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 61
- 试验地点
- 1
- 主要终点
- Mean glucose levels (assessed by blinded continuous glucose monitoring (CGM))
研究概览
简要总结
Due to reports of a severely reduced insulinotropic effect of the incretin hormone glucose-dependent insulinotropic polypeptide (GIP) in type 2 diabetes (T2D), GIP has not been considered therapeutically viable in T2D. Recently, however, tirzepatide, a novel dual incretin receptor agonist (activating both the GIP receptor and the glucagon-like peptide 1 (GLP-1) receptor) demonstrated massive improvements in glycaemic control and robust body weight losses; greater than observed with the GLP-1 receptor agonist semaglutide. However, the contribution of GIP receptor activation to these effects remains unknown. The present study will evaluate the glucose-lowering effect of GIP in the context of pharmacological GLP-1 receptor activation in patients with T2D.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 74 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial
- •Men and women 18 to 74 years of age (both inclusive) at the time of signing informed consent
- •Diagnosed with type 2 diabetes for at least six months
- •Treated with diet and exercise and/or stable metformin and/or sodium-glucose cotransporter 2 (SGLT-2) inhibitor and/or dipeptidyl-peptidase 4 inhibitor (DPP-4i) and/or sulfonylureas (SU) treatment for at least 3 months If treated with DPP-4i and/or SU, this treatment must be paused for 14 days prior to first CGM period in the trial
- •HbA1c ≥48 to ≤91 mmol/mol
- •BMI ≥25 to ≤50 kg/m2
- •Stable body weight (less than 3 kg self-reported change during the previous 90 days)
排除标准
- •For an eligible participant, all exclusion criteria must be answered "no".
- •Diagnosed with type 1 diabetes
- •Known or suspected hypersensitivity to trial product or related products
- •Acute decompensation of glycaemic control requiring immediate intensification of treatment to prevent acute complications of diabetes (e.g. diabetes ketoacidosis) which required help from doctor or hospitalisation within 90 days prior to screening
- •Previous participation in this trial. Participation is defined as signed informed consent. Participation is allowed if the protocol is updated to a newer version
- •Participation in another clinical trial within 90 days before screening
- •Woman who are pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using adequate contraceptive methods (intrauterine devices or hormonal contraception (oral contraceptive pills, implants, transdermal patches, vaginal rings or long-acting injections))
- •If previously treated with GLP-1RA, information about the time and reason for stopping will be collected. Based upon this, the eligibility will be judged by the investigator
- •Participation in an organised weight reduction programme within 3 months before screening
- •Any disorder which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol
- •Anticipated change in lifestyle (e.g. smoking, eating or exercise pattern) during the trial
- •Any laboratory safety parameter at screening outside the below extended laboratory ranges, see laboratory manual for specific values
- •Albumin outside lower normal limit (LNL) -5% and upper normal limit (UNL) +5%
- •Alanine aminotransferase (ALT) outside LNL -100% and UNL +50%
- •Creatinine outside UNL +10%
- •Haemoglobin outside LNL -5% and UNL +10%
- •Leukocytes outside LNL -20% and UNL +20%
- •Thrombocytes outside LNL -15% and UNL +15%
- •Bilirubin (total) outside UNL +15%
- •Amylase ≥ UNL +100%
- •Untreated or uncontrolled hypothyroidism/hyperthyroidism defined as thyroid-stimulating hormone (TSH) <0.4 mIU/L or > 6 mIU/L
- •Obesity related to endocrinologic disorders (e.g. Cushing Syndrome)
- •Any blood draw in excess of 25 mL in the past month, or donation of blood or plasma in excess of 400 mL within the 90 days preceding screening
- •Use of any prescription or non-prescription medication (apart from oral contraceptives, routine vitamins, occasional use of paracetamol, acetylsalicylic acid, or ibuprofen) which could interfere with pharmacokinetic or pharmacodynamic results, as judged by the investigator, such as:
- •herbal products and non-routine vitamins
- •Glucose lowering medication (except metformin)
- •medication that may cause weight gain, including systemic corticosteroids, tricyclic antidepressants, and atypical antipsychotics
- •orlistat, zonisamide, topiramate, phentermine, lorcaserin, bupropion, naltrexone or other weight loss drugs
- •Blood pressure and lipid lowering agents (e.g. statins) drugs are allowed if treatment has been stable for ≥ 1 month prior to screening and treatment should preferably be kept unchanged during the trial
- •Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2
- •History of pancreatitis (acute or chronic)
- •History of major depressive disorder or other severe psychiatric disorders, e.g. schizophrenia or bipolar disorder within the last 2 years or lifetime history of suicide attempt
- •Surgery scheduled for the trial duration period, except for minor, non-gastrointestinal surgical procedures at the discretion of the investigator
- •Sitting blood pressure (after resting for at least 5 minutes) ≥160 mmHg systolic or ≥ 100 mmHg diastolic or heart rate of ≥ 90 beats/min after resting for at least 5 minutes (if white-coat hypertension is suspected, one repeat measurement is allowed; last measure being conclusive and to be recorded in the case report form (CRF))
- •Cancer (past or present, except basal cell skin cancer or squamous cell skin cancer), which in the investigator's opinion could interfere with the results of the trial
- •Known or suspected alcohol abuse within 1 year from screening (defined as regular intake of more than 14 units weekly for men and 7 units weekly for women - one unit of alcohol equals about 300 mL of beer or lager, one glass (100 ml) of wine, or 25 ml spirits) or a positive result of an alcohol test
- •Known or suspected drug/chemical substance abuse within 1 year from screening
- •Inability or unwillingness to perform self-injection at the screening visit (with a placebo test pen)
- •Mental incapacity, language barriers or unwillingness to comply with the requirements of the protocol, which may preclude adequate understanding or co-operation during the trial, as judged by the investigator
- •Investigator, any sub-investigators, research assistants, pharmacist, trial coordinators, other staff, sponsor staff or relatives thereof directly or indirectly involved in the conduct of the trial cannot participate in the trial
研究组 & 干预措施
Semaglutide 1.34 mg/ml injections + placebo infusion
Experimental
干预措施: Semaglutide 1.34 MG/ML [Ozempic] (Drug)
placebo injections + placebo infusion
Placebo Comparator
干预措施: Semaglutide 1.34 mg/ml placebo (Other)
placebo injections + placebo infusion
Placebo Comparator
干预措施: GIP placebo (Other)
Semaglutide 1.34 mg/ml injections + GIP infusion
Experimental
干预措施: Semaglutide 1.34 MG/ML [Ozempic] (Drug)
Semaglutide 1.34 mg/ml injections + GIP infusion
Experimental
干预措施: Glucose-dependent insulinotropic polypeptide (GIP) (Drug)
placebo injections + GIP infusion
Experimental
干预措施: Glucose-dependent insulinotropic polypeptide (GIP) (Drug)
placebo injections + GIP infusion
Experimental
干预措施: Semaglutide 1.34 mg/ml placebo (Other)
Semaglutide 1.34 mg/ml injections + placebo infusion
Experimental
干预措施: GIP placebo (Other)
结局指标
主要结局
Mean glucose levels (assessed by blinded continuous glucose monitoring (CGM))
时间窗: 14-day mean glucose levels during the last 14 days of the intervention period as compared to 14-day mean glucose levels during the last 14 days of the run-in period.
The primary outcome is change in 14-day mean glucose levels (assessed by CGM) during the last 14 days of the intervention period as compared to 14-day mean glucose levels during the last 14 days of the run-in period.
次要结局
未报告次要终点
研究者
Asger Lund, MD
Associate professor, MD PhD
University Hospital, Gentofte, Copenhagen
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Short-term Effect of Intensive Insulin Therapy on Incretin SecretionType 2 DiabetesNCT00776243The Catholic University of Korea30
已完成
1 期
The Reduced Insulinotropic Effect of a Continuous Infusion Relative to a Bolus Injection of GIPType 2 DiabetesNCT02673554Diabeteszentrum Bad Lauterberg im Harz30
已完成
不适用
Insulinotropic Effect of GIP and GLP-1 Before and After Reduced Glucose ToleranceDeteriorated Glucose HomeostasisInactivityInsulin ResistanceNCT01173978Glostrup University Hospital, Copenhagen10
Unknown
不适用
The Influence Of GIP (Glucose-Dependent Insulinotropic Polypeptide) Infusion On Human Adipose Tissue: An In Vivo StudyAdipose TissueNCT00809029Liverpool University Hospitals NHS Foundation Trust12
Unknown
不适用
Effects of Short-term Intensive Insulin Therapy in Newly Diagnosed Type 2 Diabetes PatientsType 2 Diabetes MellitusNCT01588743Li Guangwei130